BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Gabr SA, Alghadir AH. Handgrip Strength and Vitamin D as Predictors of Liver Fibrosis and Malnutrition in Chronic Hepatitis C Patients. Dis Markers 2021;2021:6665893. [PMID: 33884041 DOI: 10.1155/2021/6665893] [Reference Citation Analysis]
2 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
3 Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World J Gastroenterol 2022; 28(2): 263-274 [DOI: 10.3748/wjg.v28.i2.263] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc 2020;119:1593-600. [PMID: 32839045 DOI: 10.1016/j.jfma.2020.08.010] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liang PC, Lin PC, Huang CI, Huang CF, Yeh ML, Zeng YS, Hsu WY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chiou SS, Yu ML. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. J Formos Med Assoc 2018;117:14-23. [PMID: 29097076 DOI: 10.1016/j.jfma.2017.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
6 Takata R, Nishikawa H, Enomoto H, Iwata Y, Ishii A, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Relationship between skeletal muscle mass and liver fibrosis markers for patients with hepatitis C virus related liver disease. Medicine (Baltimore) 2017;96:e8761. [PMID: 29310350 DOI: 10.1097/MD.0000000000008761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Yu ML, Tsai WL, Chu CJ, Kao JH. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. Kaohsiung J Med Sci 2021;37:245-52. [PMID: 33089964 DOI: 10.1002/kjm2.12317] [Reference Citation Analysis]
8 Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH;  REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587-598. [PMID: 31463665 DOI: 10.1007/s12072-019-09974-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
9 Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. J Infect Dis 2019;220:557-66. [PMID: 30957170 DOI: 10.1093/infdis/jiz154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
10 Yu ML. Reply to "The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world". J Formos Med Assoc 2018;117:1038-9. [PMID: 30287149 DOI: 10.1016/j.jfma.2018.09.014] [Reference Citation Analysis]
11 Lu MY, Chen CT, Shih YL, Tsai PC, Hsieh MH, Huang CF, Yeh ML, Huang CI, Wang SC, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML, Chang WY. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. Sci Rep 2021;11:8554. [PMID: 33879825 DOI: 10.1038/s41598-021-87975-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tai CM, Yen YC, Bair MJ, Tseng CH, Chang TT, Huang CF, Yeh ML, Dai CY, Chuang WL, Yu ML, Huang JF. Integrated care for methadone maintenance patients with hepatitis C virus infection. Kaohsiung J Med Sci 2019;35:501-7. [PMID: 31087764 DOI: 10.1002/kjm2.12086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Oliveira FB, Boza JC, Pires GC, Barone CR, Rossi SD, Silva M, Bonamigo RR. Direct-acting antiviral drugs are triggers for psoriasis: report of three cases. Int J Dermatol 2018;57:e95-7. [PMID: 29974944 DOI: 10.1111/ijd.14137] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118:556-64. [PMID: 30527566 DOI: 10.1016/j.jfma.2018.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol 2022; 28(1): 140-153 [DOI: 10.3748/wjg.v28.i1.140] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Ke CK, Yu ML. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). Open Forum Infect Dis 2020;7:ofaa397. [PMID: 33376753 DOI: 10.1093/ofid/ofaa397] [Reference Citation Analysis]
18 Jang TY, Liang PC, Liu TW, Wei YJ, Yeh ML, Hsu CT, Hsu PY, Lin YH, Hsieh MH, Huang CI, Huang CF, Lin ZY, Chen SC, Huang JF, Dai CY, Yu ML, Chuang WL. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. J Chin Med Assoc 2021;84:255-60. [PMID: 33433134 DOI: 10.1097/JCMA.0000000000000478] [Reference Citation Analysis]
19 Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020. Kaohsiung J Med Sci 2021;37:7-11. [PMID: 33337581 DOI: 10.1002/kjm2.12345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
21 Gardner SD, Kim J, Baptiste-Brown S, Lopez V, Hamatake R, Gan J, Edwards S, Elko-Simms L, Dumont EF, Leivers M, Hong Z, Paff MT. GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects. J Viral Hepat 2018;25:19-27. [PMID: 28692182 DOI: 10.1111/jvh.12753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
22 Titze-de-Almeida R, David C, Titze-de-Almeida SS. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. Pharm Res 2017;34:1339-63. [PMID: 28389707 DOI: 10.1007/s11095-017-2134-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 19.0] [Reference Citation Analysis]
23 Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore) 2017;96:e6984. [PMID: 28562549 DOI: 10.1097/MD.0000000000006984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
24 Nishikawa H, Nishimura T, Enomoto H, Iwata Y, Ishii A, Miyamoto Y, Ishii N, Yuri Y, Takata R, Hasegawa K, Nakano C, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Nishiguchi S, Iijima H. Impact of Virtual Touch Quantification in Acoustic Radiation Force Impulse for Skeletal Muscle Mass Loss in Chronic Liver Diseases. Nutrients 2017;9:E620. [PMID: 28621757 DOI: 10.3390/nu9060620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]